Bicara Therapeutics Inc. closes oversubscribed equity offering to fund ficerafusp alfa advancement

Bicara Therapeutics Inc. closes oversubscribed equity offering to fund ficerafusp alfa advancement
Bicara closes equity offering

Bicara Therapeutics Inc. has announced the successful closing of its oversubscribed follow-on equity offering.

The proceeds are set to accelerate the development and manufacturing of the company’s lead candidate, ficerafusp alfa, with an added focus on a less frequent dosing option. The new funding will also bolster Bicara Therapeutics Inc.'s commercial and regulatory readiness activities in the U.S., positioning the company for upcoming milestones. Specific financing terms and investors were not detailed in the announcement.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.
Weekly Top Bonuses
up to $2,500
deposit bonus for all clients
CLAIM BONUS
Your capital is at risk.